Completed PHASE1 INTERVENTIONAL 1-arm NCT02805244

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

A Phase 1, Open-label, Single Dose, Mass Balance Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of 14C-JTZ-951 in Male Subjects With End-stage Renal Disease Receiving Hemodialysis

Sponsor: Akros Pharma Inc.

Conditions Anemia of Chronic Kidney Disease

Interventions JTZ-951, 14C-JTZ-951

Updated 6 times since 2017 Last updated: Nov 28, 2016 Started: Jun 30, 2016 Primary completion: Sep 30, 2016 Completion: Sep 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Anemia of Chronic Kidney Disease, this trial is completed. The trial is conducted by Akros Pharma Inc. and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akros Pharma Inc.

Data source: Akros Pharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States